Testing chemotherapy choices for early breast cancer after surgery
Part of Cancer, Skin clinical trials.
This Phase 1 study tests different chemotherapy approaches in people with breast cancer that has been surgically removed but is early stage. It aims to find a chemotherapy plan that’s safe and works well right after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- Your breast cancer was confirmed as infiltrating ductal carcinoma (by biopsy/pathology)
- You must have generally healthy “major organs” and not severe problems with liver, heart, or other key organs
- Your blood counts must be strong enough (white blood cells and neutrophils, platelets, and hemoglobin) and you should not need transfusions
- You must be in an early stage (at least stage IA) and not have distant metastasis
- You need to be able to sign informed consent and have a good energy level (WHO performance status 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares an “albumin-bound” form of paclitaxel versus other taxane chemotherapy options after breast surgery. It’s for people with HER2-negative, higher-risk breast cancer to see which approach works better in real-world care.
This trial tests a chemotherapy combination (CMC) for people with early-stage, hormone receptor-positive, HER2-negative breast cancer who have a high risk of recurrence. It aims to understand if this oral regimen is effective and tolerable.
This trial tests whether it is safe to skip chemotherapy after surgery for certain patients with early-stage, hormone-receptor positive, HER2-negative breast cancer that has not spread to lymph nodes. Instead, they would receive hormone therapy plus a targeted CDK4/6 inhibitor (a pill that blocks cancer cell growth).
This Phase 3 trial studies different ways of giving common chemotherapy drugs (anthracyclines and taxanes) for locally advanced breast cancer that is HER2-negative. It aims to see which order or “sequencing” may work better for people like you.
This trial tests whether adding the antibiotic doxycycline to standard chemotherapy before surgery can better target breast cancer stem cells in people with ER-positive, HER2-negative breast cancer. The goal is to improve treatment response.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.